27733154|t|Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma
27733154|a|This study addresses involvement of major 5-fluorouracil (5-FU) pathway genes in the prognosis of colorectal carcinoma patients. Testing set and two validation sets comprising paired tumor and adjacent mucosa tissue samples from 151 patients were used for transcript profiling of 15 5-FU pathway genes by quantitative real-time PCR and DNA methylation profiling by high resolution melting analysis. Intratumoral molecular profiles were correlated with clinical data of patients. Protein levels of two most relevant candidate markers were assessed by immunoblotting. Downregulation of DPYD and upregulation of PPAT, UMPS, RRM2, and SLC29A1 transcripts were found in tumors compared to adjacent mucosa in testing and validation sets of patients. Low RRM2 transcript level significantly associated with poor response to the first-line palliative 5-FU -based chemotherapy in the testing set and with poor disease-free interval of patients in the validation set irrespective of 5-FU treatment. UPP2 was strongly methylated while its transcript absent in both tumors and adjacent mucosa. DPYS methylation level was significantly higher in tumor tissues compared to adjacent mucosa samples. Low intratumoral level of UPB1 methylation was prognostic for poor disease-free interval of the patients (P = 0.0002). The rest of the studied 5-FU genes were not methylated in tumors or adjacent mucosa. The observed overexpression of several 5-FU activating genes and DPYD downregulation deduce that chemotherapy naïve colorectal tumors share favorable gene expression profile for 5-FU therapy. Low RRM2 transcript and UPB1 methylation levels present separate poor prognosis factors for colorectal carcinoma patients and should be further investigated.
27733154	21	35	5-fluorouracil	T103	UMLS:C0016360
27733154	36	43	pathway	T038	UMLS:C1704259
27733154	44	49	genes	T017	UMLS:C0017337
27733154	53	73	colorectal carcinoma	T038	UMLS:C0009402
27733154	79	84	study	T062	UMLS:C2603343
27733154	116	130	5-fluorouracil	T103	UMLS:C0016360
27733154	132	136	5-FU	T103	UMLS:C0016360
27733154	138	145	pathway	T038	UMLS:C1704259
27733154	146	151	genes	T017	UMLS:C0017337
27733154	159	168	prognosis	T058	UMLS:C0033325
27733154	172	192	colorectal carcinoma	T038	UMLS:C0009402
27733154	203	214	Testing set	T170	UMLS:C0150098
27733154	223	238	validation sets	T170	UMLS:C0282574
27733154	257	262	tumor	T038	UMLS:C0027651
27733154	267	275	adjacent	T082	UMLS:C0205117
27733154	276	289	mucosa tissue	T017	UMLS:C0026724
27733154	330	340	transcript	T103	UMLS:C1519595
27733154	341	350	profiling	T062	UMLS:C0079247
27733154	357	361	5-FU	T103	UMLS:C0016360
27733154	362	369	pathway	T038	UMLS:C1704259
27733154	370	375	genes	T017	UMLS:C0017337
27733154	379	405	quantitative real-time PCR	T062	UMLS:C3179034
27733154	410	435	DNA methylation profiling	T062	UMLS:C1880239
27733154	473	485	Intratumoral	T082	UMLS:C1517564
27733154	526	539	clinical data	T170	UMLS:C1516606
27733154	553	567	Protein levels	T033	UMLS:C0428479
27733154	599	606	markers	T201	UMLS:C0005516
27733154	624	638	immunoblotting	T058	UMLS:C0020985
27733154	640	654	Downregulation	T038	UMLS:C0013081
27733154	658	662	DPYD	T017	UMLS:C1366555
27733154	667	679	upregulation	T038	UMLS:C0041904
27733154	683	687	PPAT	T017	UMLS:C1418780
27733154	689	693	UMPS	T017	UMLS:C1421354
27733154	695	699	RRM2	T017	UMLS:C1335649
27733154	705	712	SLC29A1	T017	UMLS:C1420171
27733154	713	724	transcripts	T103	UMLS:C1519595
27733154	739	745	tumors	T038	UMLS:C0027651
27733154	758	766	adjacent	T082	UMLS:C0205117
27733154	767	773	mucosa	T017	UMLS:C0026724
27733154	777	784	testing	T170	UMLS:C0150098
27733154	789	804	validation sets	T170	UMLS:C0282574
27733154	822	826	RRM2	T017	UMLS:C1335649
27733154	827	837	transcript	T103	UMLS:C1519595
27733154	917	921	5-FU	T103	UMLS:C0016360
27733154	929	941	chemotherapy	T058	UMLS:C3665472
27733154	949	960	testing set	T170	UMLS:C0150098
27733154	1016	1030	validation set	T170	UMLS:C0282574
27733154	1047	1051	5-FU	T103	UMLS:C0016360
27733154	1052	1061	treatment	T058	UMLS:C0087111
27733154	1063	1067	UPP2	T017	UMLS:C1427883
27733154	1102	1112	transcript	T103	UMLS:C1519595
27733154	1128	1134	tumors	T038	UMLS:C0027651
27733154	1139	1147	adjacent	T082	UMLS:C0205117
27733154	1148	1154	mucosa	T017	UMLS:C0026724
27733154	1156	1160	DPYS	T017	UMLS:C1414144
27733154	1161	1172	methylation	T038	UMLS:C0376452
27733154	1207	1220	tumor tissues	T017	UMLS:C0475358
27733154	1233	1241	adjacent	T082	UMLS:C0205117
27733154	1242	1248	mucosa	T017	UMLS:C0026724
27733154	1262	1274	intratumoral	T082	UMLS:C1517564
27733154	1284	1288	UPB1	T017	UMLS:C1424165
27733154	1289	1300	methylation	T038	UMLS:C0376452
27733154	1305	1315	prognostic	T170	UMLS:C0220901
27733154	1401	1405	5-FU	T103	UMLS:C0016360
27733154	1406	1411	genes	T017	UMLS:C0017337
27733154	1435	1441	tumors	T038	UMLS:C0027651
27733154	1445	1453	adjacent	T082	UMLS:C0205117
27733154	1454	1460	mucosa	T017	UMLS:C0026724
27733154	1475	1489	overexpression	T038	UMLS:C0017262
27733154	1501	1505	5-FU	T103	UMLS:C0016360
27733154	1506	1522	activating genes	T017	UMLS:C0017337
27733154	1527	1531	DPYD	T017	UMLS:C1366555
27733154	1532	1546	downregulation	T038	UMLS:C0013081
27733154	1559	1571	chemotherapy	T058	UMLS:C3665472
27733154	1572	1595	naïve colorectal tumors	T038	UMLS:C0009404
27733154	1640	1644	5-FU	T103	UMLS:C0016360
27733154	1645	1652	therapy	T058	UMLS:C0087111
27733154	1658	1662	RRM2	T017	UMLS:C1335649
27733154	1663	1673	transcript	T103	UMLS:C1519595
27733154	1678	1682	UPB1	T017	UMLS:C1424165
27733154	1683	1694	methylation	T038	UMLS:C0376452
27733154	1724	1741	prognosis factors	T201	UMLS:C1514474
27733154	1746	1766	colorectal carcinoma	T038	UMLS:C0009402